Página principal > Resultados de la búsqueda: de Jonge, M.
  Consejos para la búsqueda
Búsqueda avanzada
Buscar colecciones:
Ordenar por: Mostrar resultados: Formato de visualización:
Resultados globales: 3 registros encontrados en 0.02 segundos.
Artículos, Encontrados 3 registros
Artículos Encontrados 3 registros  
1.
0 p, 567.1 KB Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer : clinical and biomarker results from a phase I trial / Schuler, M. (German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany) ; Berardi, R. (Università Politecnica delle Marche-Ospedali Riuniti) ; Lim, W.-T (National Cancer Centre Singapore) ; de Jonge, M. (Erasmus MC Cancer Center, Rotterdam) ; Bauer, Todd M (Sarah Cannon Research Institute, and Tennessee Oncology) ; Azaro, Analía (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ; Gottfried, M. (Oncology Institute of Meir Medical Center) ; Han, J.Y (Center for Lung Cancer, National Cancer Center (Corea del Sud)) ; Lee, D. H. (University of Ulsan College of Medicine (República de Corea)) ; Wollner, M. (Rambam Health Care Campusm (Israel)) ; Hong, David (MD Anderson Cancer Center (Estats Units d'Amèrica)) ; Vogel, A. (Hannover Medical School (Alemanya)) ; Delmonte, A. (Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori) ; Akimov, Mikhail (Novartis Pharma (Siïssa)) ; Ghebremariam, S. (Oncology Global Development-BDM) ; Cui, X. (Novartis Institutes for Biomedical Research) ; Nwana, N. (Oncology Precision Medicine) ; Giovannini, M. (Novartis Pharmaceuticals Corporation(Estats Units d'Amèrica)) ; Kim, T. M. (Seoul National University Hospital)
Dysregulation of receptor tyrosine kinase MET by various mechanisms occurs in 3%-4% of non-small-cell lung cancer (NSCLC) and is associated with unfavorable prognosis. While MET is a validated drug target in lung cancer, the best biomarker strategy for the enrichment of a susceptible patient population still remains to be defined. [...]
2020 - 10.1016/j.annonc.2020.03.293
Annals of oncology, Vol. 31 (march 2020) , p. 789-797  
Registro completo - Creative Commons
2.
11 p, 632.8 KB Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma / Vieito, María (Vall d'Hebron Institut d'Oncologia) ; Simonelli, Matteo (Humanitas Research Hospital (Itàlia)) ; de Vos, Filip (University Medical Center Utrecht) ; Geurts, Marjolein (Erasmus MC Cancer Institute (Holanda)) ; Lorenzi, Elena (Humanitas Research Hospital (Itàlia)) ; Macchini, Marina (San Raffaele Scientific Institute (Itàlia)) ; van den Bent, Martin J (Erasmus MC Cancer Institute (Holanda)) ; Del Conte, Gianluca (San Raffaele Scientific Institute (Itàlia)) ; de Jonge, Maja (Erasmus MC Cancer Institute (Holanda)) ; Martín-Soberón, Maria Cruz (Hospital Universitario 12 de Octubre (Madrid)) ; Amoroso, Barbara (A Bristol Myers Squibb Company (Sevilla)) ; Sanchez-Perez, Tania (Bristol Myers Squibb Company (Sevilla)) ; Zuraek, Marlene (Bristol Myers Squibb (Estats Units d'Amèrica)) ; Hanna, Bishoy (Bristol Myers Squibb (Estats Units d'Amèrica)) ; Aronchik, Ida (Bristol Myers Squibb (Estats Units d'Amèrica)) ; Filvaroff, Ellen (Bristol Myers Squibb (Estats Units d'Amèrica)) ; Chang, Henry (Bristol Myers Squibb (Estats Units d'Amèrica)) ; Mendez, Cristina (Bristol Myers Squibb (Sevilla)) ; Arias Parro, Marina (Bristol Myers Squibb (Suïssa)) ; Wei, Xin (Bristol Myers Squibb (Estats Units d'Amèrica)) ; Nikolova, Zariana (Bristol Myers Squibb (Sevilla)) ; Sepulveda, Juan Manuel (Hospital Universitario 12 de Octubre (Madrid)) ; Universitat Autònoma de Barcelona
Standard-of-care treatment for newly diagnosed glioblastoma (ndGBM), consisting of surgery followed by radiotherapy (RT) and temozolomide (TMZ), has improved outcomes compared with RT alone; however, prognosis remains poor. [...]
2022 - 10.1093/noajnl/vdac146
Neuro-oncology Advances, Vol. 4 (october 2022)  
Registro completo - Creative Commons
3.
13 p, 501.3 KB A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function / Azaro, Analía (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ; Rodón, Jordi (Hospital Universitari Vall d'Hebron) ; Machiels, Jean-Pascal (Institut Roi Albert II (Bèlgica). Department of Medical Oncology) ; Rottey, Sylvie (Universitair Ziekenhuis Gent) ; Damian, Silvia (National Cancer Institute of Milan) ; Baird, Richard (Early Phase Clinical Trials Team, Department of Oncology, University of Cambridge, Cambridge, UK) ; Garcia-Corbacho, Javier (Early Phase Clinical Trials Team, Department of Oncology, University of Cambridge, Cambridge, UK) ; Mathijssen, Ron H. J. (Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands) ; Clot, Pierre-François (Sanofi, Chilly-Mazarin, France) ; Wack, Claudine (Sanofi, Chilly-Mazarin, France) ; Shen, Liji (Sanofi, Bridgewater, NJ USA) ; de Jonge, Maja (Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands)
Limited data are available on cabazitaxel pharmacokinetics in patients with renal impairment. This open-label, multicenter study assessed cabazitaxel in patients with advanced solid tumors and normal or impaired renal function. [...]
2016 - 10.1007/s00280-016-3175-7
Cancer Chemotherapy and Pharmacology, Vol. 78 (october 2016) , p. 1185-1197  
Registro completo - Creative Commons

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.
Depósito Digital de Documentos de la UAB :: Buscar :: Enviar :: Personalizar :: Ayuda
Powered by Invenio v1.1.6
Mantenido por ddd.bib@uab.cat  :: Metadatos sujetos a:
Colaboramos